-
Risk of Adenocarcinoma in Barretts Esophagus; Long-Term Effect of Doxazosin, Finasteride, and Combination for BPH; Once Daily Valacyclovir to Reduce Herpes Transmission
-
The FDA has approved the first once-daily, quaternary ammonium, anticholinergic bronchodilator for the treatment of chronic obstructive pulmonary disease.
-
As determined by process-of-care measurement, adverse event occurrence, and patient satisfaction, quality of care is compromised by infection control procedures.
-
For unvaccinated or high-risk vaccinated patients during the influenza season, empirical oseltamivir treatment is cost-effective. For other patients, rapid diagnostic testing followed by treatment with oseltamivir is cost-effective. Empirical amantadine treatment offers a low-cost alternative if patients cannot afford oseltamivir.
-
Plan now to attend the HIV Prevention Leadership Summit, scheduled for June 16-19, 2004, at the Georgia World Congress Center in Atlanta.
-
Check the following web sites to get teen-friendly information to share with your adolescent patients.
-
Circle Aug. 12-15, 2004, on the calendar for the Minority Womens Health Summit sponsored by the Office of Public Health and Science, Office on Womens Health. The summit, Women of Color, Taking Action for a Healthier Life: Progress, Partnerships and Possibilities, will build upon the first national conference held in 1997.
-
Over the past decade, 18 states have obtained federal approval to extend eligibility for Medicaid-covered family planning services to individuals who would otherwise not be eligible. The first national evaluation of these efforts found that every one of the programs studied not only met the requirement that they not result in additional costs to the federal government, but actually saved money.
-
What is your approach when it comes to repeat doses of the levonorgestrel-only emergency contraceptive pill (ECP), Plan B (Womens Capital Corp., Washington, DC)? Comments on this question are offered by Contraceptive Technology Update Editorial Advisory Board members.
-
The Today contraceptive sponge awaits the results of a Food and Drug Administration (FDA) review to return to the shelves in the United States. After being approved by the FDA in 1983, the sponge achieved considerable popularity before production was discontinued in 1995. Since then, Allendale (NJ) Pharmaceuticals has purchased rights to the Today sponge and has been working to bring the product back to the United States.
